ATTO
Atento SA
NASDAQ · Healthcare · Biotechnology · US
$15.27
−3.35%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 450.0K | 1.4M | — |
| Cost of Revenue | 631.0K | 804.0K | 313.0K |
| Gross Profit | (181.0K) | 546.0K | (313.0K) |
| Operating Expenses | |||
| R&D Expense | 61.1M | 54.2M | 33.9M |
| SG&A Expense | 13.2M | 13.6M | 7.4M |
| General & Admin Expense | 3.0M | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | 74.3M | 67.7M | 41.2M |
| Cost and Expenses | 74.9M | 68.5M | 41.6M |
| Operating Income (EBIT) | (74.5M) | (67.2M) | (41.6M) |
| Non-Operating | |||
| Interest Income | 5.6M | 6.6M | 3.4M |
| Interest Expense | — | — | — |
| Net Interest Income | 5.6M | 6.6M | 3.4M |
| Other Non-Op Income/Expense | 5.5M | 6.5M | 1.8M |
| Non-Operating Income (excl Interest) | — | — | — |
| EBT (Pre-Tax Income) | (68.9M) | (60.6M) | (39.8M) |
| Income Tax Expense | — | — | — |
| Bottom Line | |||
| Net Income | (68.9M) | (60.6M) | (39.8M) |
| Earnings from Cont. Ops | (68.9M) | (60.6M) | (39.8M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (69.2M) | (60.9M) | (45.0M) |
| Per Share | |||
| Basic EPS | ($1.89) | ($1.42) | ($1.05) |
| Diluted EPS | ($1.89) | ($1.42) | ($1.05) |
| Revenue Per Share | $0.01 | $0.03 | $0.00 |
| Shares | |||
| Basic Shares Outstanding | 45.7M | 43.0M | 43.0M |
| Diluted Shares Outstanding | 45.7M | 43.0M | 43.0M |
| Profitability Metrics | |||
| EBITDA | (73.6M) | (66.4M) | (41.2M) |
| D&A | 838.0K | 804.0K | 313.0K |
| EBIT | (74.5M) | (67.2M) | (41.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026